Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy

To validate the American Thyroid Association (ATA) initial risk of recurrence scheme and the Memorial Sloan Kettering Cancer Center (MSKCC) response to therapy re‐stratification approach in a large cohort of patients with differentiated thyroid cancer (DTC) treated outside of the United States.

[1]  R. Tuttle,et al.  In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. , 2011, Thyroid : official journal of the American Thyroid Association.

[2]  G. Cevenini,et al.  Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. , 2011, European journal of endocrinology.

[3]  C. Coeli,et al.  CLINICS 2011;66(2):281-286 DOI:10.1590/S1807-59322011000200017 CLINICAL SCIENCE , 2022 .

[4]  F. Scorza,et al.  The stability of fish populations: how changes in the environment may affect people with epilepsy , 2011, Clinics.

[5]  M. Kreissl,et al.  Favourable course of disease after incomplete remission on 131I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  J. Shah,et al.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.

[7]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[8]  Mark Dowar,et al.  Influence of age and primary tumor size on the risk for residual/recurrent well‐differentiated thyroid carcinoma , 2009, Head & neck.

[9]  Tuttle Rm.  Risk-Adapted Management of Thyroid Cancer , 2008 .

[10]  R. Tuttle.  Risk-adapted management of thyroid cancer. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[11]  L. Ward,et al.  [Thyroid nodules and differentiated thyroid cancer: Brazilian consensus]. , 2007, Arquivos brasileiros de endocrinologia e metabologia.

[12]  Ana Luiza Maia,et al.  Thyroid nodules and differentiated thyroid cancer: Brazilian consensus , 2007 .

[13]  W. Wiersinga,et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.

[14]  A. Alzahrani,et al.  Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer , 2005, Journal of endocrinological investigation.

[15]  E. Yıldırım.  A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems. , 2005, Journal of the American College of Surgeons.

[16]  I. Sugitani,et al.  A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. , 2004, Surgery.

[17]  S. Noguchi,et al.  Classification of papillary cancer of the thyroid based on prognosis , 1994, World Journal of Surgery.

[18]  E. Baudin,et al.  Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. , 2003, The Journal of clinical endocrinology and metabolism.

[19]  K. Ain,et al.  Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. , 1995, The Journal of clinical endocrinology and metabolism.

[20]  J. Shah,et al.  Intermediate-risk group for differentiated carcinoma of thyroid. , 1994, Surgery.

[21]  L. Akslen.  Prognostic importance of histologic grading in papillary thyroid carcinoma , 1993, Cancer.

[22]  E. Kaplan,et al.  Natural history, treatment, and course of papillary thyroid carcinoma. , 1990, The Journal of clinical endocrinology and metabolism.

[23]  B. Cady,et al.  An expanded view of risk-group definition in differentiated thyroid carcinoma. , 1988, Surgery.

[24]  W. Taylor,et al.  Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. , 1987, Surgery.

[25]  M. van Glabbeke,et al.  A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. , 1979, European journal of cancer.